2021, Number 3
El COVID-19 en pacientes pediátricos atendidos en la Provincia de Villa Clara
Language: Spanish
References: 22
Page: 413-424
PDF size: 438.23 Kb.
ABSTRACT
Introduction: the coronavirus disease 2019 in children does not present a high casuistry globally and it is characterized by presenting a wide clinical spectrum. The evolution of the disease is less severe in kids than in adults according to the data which was provided by some studies in China and other countries.Objective: to describe the clinical aspects, the laboratory one and the treatment of COVID-19 in the pediatric population that was treated.
Methods: a descriptive cross-sectional study from Villa Clara Province was carried out in 43 patients that were diagnosed with COVID-19 from March to October 2020, the group of people was selected by non-probabilistic sampling.
Results: a total of 43 children were affected, the older than 15 years had more predomination, 20 children had the disease asymptomatically and the rest presented mild symptoms. Cutaneous manifestations and mild respiratory symptoms were highlighted. 17 patients presented mild leukopenia in the laboratory tests at 72 hours, the pulmonary radiological pattern was normal except in 2 children. The treatment was applied to everybody according to the actual protocol (kaletra, chloroquine and interferon) and it showed excellent results.
Conclusions: the clinical diagnosis favored to register a higher incidence of the disease in the patients older than 15 years, the asymptomatic cases predominated and the patients developed mild symptoms of the disease, the majority presented normal laboratory values and chest X-rays, the treatment was based on triple therapy according to the Cuban action protocol at that time.
REFERENCES
CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children —United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 Apr [citado04/05/2020];69(14):422-426. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147903/. https://dx.doi.org/10.15585/mmwr.mm6914e4
Santana Espinosa MC, Álvarez Lauzerique ME, Torres Esperón JM, Castro Pacheco BL.Contexto sanitario de niños y adolescentes infestados por la COVID-19 en zonas geográficas seleccionadas.Estudio entre marzo y mayo 2020. La Habana: Escuela Nacional de Salud Pública de Cuba; 2020 [citado 04/12/2020]. Disponible en: https://www.unicef.org/cuba/media/1921/file/COVID-19_II%20pediatr%C3%ADa.pdf%20.pdf
Atamari Anahui N, Cruz-Nina N, Condori Huaraka M, Nuñez Paucar H, Ordoñez Linares M. Caracterización de la enfermedad por coronavirus 2019 (COVID-19) en niños y adolescentes en países de América Latina y El Caribe: estudio descriptivo. Medwave [Internet]. 2020 [citado 04/12/2020];20(8):e8025. Disponible en: https://www.medwave.cl/link.cgi/Medwave/Estudios/Investigacion/8025.act.https://doi.org/10.5867/medwave.2020.08.8025
Asociación Médica Mundial. Declaración de Helsinki de la AMM –Principios éticos para las investigaciones médicas en seres humanos [Internet]. Ferney-Voltaire, Francia: AMM; 2020 [citado 04/12/2020]. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
Centro de Coordinación de Alertasy Emergencias Sanitarias. Información científica-técnica. Enfermedad por coronavirus, COVID-19 [Internet]. Madrid: CCAES;2020 [citado 04/12/2020]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/20200417_ITCoronavirus.pdf
Calvo C, García López-Hortelano M, Carlos Vicente JC, Vázquez Martínez JL. Recomendaciones sobre el manejo clínico de la infección por el «nuevo coronavirus» SARS-CoV2. Grupo de trabajo de la Asociación Española de Pediatría (AEP). An Pediatr (Barc) [Internet]. 2020 [citado 04/12/2020];92(4):241.e1-241.e11. Disponible en: https://www.sciencedirect.com/science/article/pii/S169540332030076X. https://doi.org/10.1016/j.anpedi.2020.02.001
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet [Internet]. 2020 [citado04/05/2020];39(10223):507-513. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135076/. https://doi.org/10.1016/S0140-6736(20)30211-7
Centro Nacional de Epidemiología, Instituto de Salud Carlos III. Informe sobre la situación de COVID-19 en España. Informe COVID-19 No.14, 24 de marzo de 2020 [Internet]. Madrid: Centro Nacional de Epidemiología; 2020 [citado 12/05/2020]. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20n%C2%BA%2014.%20Situaci%C3%B3n%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2024%20marzo%20de%202020.pdf
Fuk-Woo Chan J, Yuan S, Kin-Hahg K, Kai-Wang To K, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet [Internet]. 2020 Feb [citado 04/12/2020];395(10223):514-523. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159286/. https://doi.org/10.1016/S0140-6736(20)30154-9
Qilin L, Xiuli D, Geqing X, Heng-Gui C, Fenghua C, Zhi G, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. EClinicalMedicine [Internet]. 2020 Jun [citado 16/06/2020];23(2020):100375. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196382/. https://doi.org/10.1016/j.eclinm.2020.100375
Sánchez Vera N, Saavedra Hernández D, Hidalgo Mesa CJ, Aguila López M, Abreu Gutiérrez G, Herrera González V, et al. Parámetros de laboratorio clínico en pacientes con la COVID-19. Rev Cub Med Mil [Internet]. 2021 [citado 19/06/2021];50(2):e02101171. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/1171/910
González Tabares R, Acosta González FA, Oliva Villa E, Rodríguez Reyes SF, Cabeza Echevarría I. Predictores de mal pronóstico en pacientes con la COVID-19. Rev Cub Med Mil [Internet]. 2020 Dic [citado 04/12/2020];49(4):e918. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572020000400020
Acosta Torres J, Pérez Cutiño M, Rodríguez Prieto M, Morales González A. COVID-19 en pediatría: aspectos clínicos, epidemiológicos, inmunopatogenia, diagnóstico y tratamiento. Rev Cubana Pediatr [Internet]. 2020 [citado 04/12/2020];92(Suppl 1):e1152. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312020000500007
European Commision. Anexo I Ficha técnica o resumen de las características del producto. Kaletra 133,3 mg/33,3 mg cápsulas blandas lopinavir/ritonavir. Public Health – Union Register of medical products [Internet]. Bruselas: European Commision; 2020 [citado 04/12/2020]. Disponible en: https://ec.europa.eu/health/documents/community-register/2010/2010121394669/anx_94669_es.pdf
Herrera-Lasso Regás V, Dordal Culla MT, Lleonart Bellfill R. Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2. Med Clin (Barc) [Internet]. 2020 Nov [citado 04/12/2020];155(10):448-453. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346774/